晚期胃癌患者化疗联合抗程序性死亡受体-1单克隆抗体（替雷利珠单抗）治疗期间发生肾上腺功能不全：病例系列
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: case series.
作者信息
Baek Jin Ho
机构信息
Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.
出版信息
J Yeungnam Med Sci. 2022 Jan;39(1):62-66. doi: 10.12701/yujm.2021.00934. Epub 2021 Apr 19.
Abstract
Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (, Baize'an; BeiGene Ltd.) therapy in patients with advanced gastric cancer. Adrenal insufficiency developed after 6 and 13 cycles of treatment and was well controlled with hydrocortisone. The patients also developed hypothyroidism, which was managed with levothyroxine. Two patients showed a partial response, and one patient out of two achieved a near-complete response, sustaining over 11 months. Increased awareness of ICI-related adrenal insufficiency is crucial for early detection and prompt management of patients treated with ICIs.
摘要
免疫检查点抑制剂（ICI）相关的肾上腺功能不全较为罕见，但在接受ICI治疗的患者中可能会成为严重的不良事件。本病例报告记录了2例晚期胃癌患者在化疗加替雷利珠单抗（百泽安；百济神州有限公司）治疗期间发生肾上腺功能不全的情况。肾上腺功能不全分别在治疗6个周期和13个周期后出现，通过氢化可的松得到良好控制。患者还出现了甲状腺功能减退，通过左甲状腺素进行治疗。2例患者出现部分缓解，其中1例达到近完全缓解，持续超过11个月。提高对ICI相关肾上腺功能不全的认识对于早期发现和及时处理接受ICI治疗的患者至关重要。
相似文献
1
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: case series.晚期胃癌患者化疗联合抗程序性死亡受体-1单克隆抗体（替雷利珠单抗）治疗期间发生肾上腺功能不全：病例系列
J Yeungnam Med Sci. 2022 Jan;39(1):62-66. doi: 10.12701/yujm.2021.00934. Epub 2021 Apr 19.
2
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.帕米帕利联合替雷利珠单抗治疗晚期实体瘤患者的多中心、开放标签、1a/b 期剂量递增研究结果。
Lancet Oncol. 2019 Sep;20(9):1306-1315. doi: 10.1016/S1470-2045(19)30396-1. Epub 2019 Aug 1.
3
Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature.替雷利珠单抗致免疫检查点抑制剂相关肾上腺功能减退和银屑病 1 例报告及文献复习。
Medicine (Baltimore). 2024 Mar 22;103(12):e37562. doi: 10.1097/MD.0000000000037562.
4
Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report.甲状腺功能减退和垂体功能减退作为胃癌肝转移腹腔镜肝切除术后即刻使用乐伐替尼联合帕博利珠单抗治疗引起的免疫相关不良事件：一例报告
Surg Case Rep. 2021 Dec 20;7(1):267. doi: 10.1186/s40792-021-01346-w.
5
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review.替雷利珠单抗诱发的严重甲状腺毒症：一例报告及文献综述
Front Oncol. 2023 Oct 2;13:1190491. doi: 10.3389/fonc.2023.1190491. eCollection 2023.
6
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.免疫检查点抑制剂治疗引起的垂体炎患者的继发性肾上腺功能不全的恢复。
J Immunother Cancer. 2019 Sep 12;7(1):248. doi: 10.1186/s40425-019-0729-3.
7
Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report.替雷利珠单抗免疫检查点抑制剂治疗晚期非小细胞肺癌患者后出现的免疫相关多器官损伤：一例报告
Front Oncol. 2021 Sep 2;11:664809. doi: 10.3389/fonc.2021.664809. eCollection 2021.
8
Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management.免疫检查点抑制剂相关性肾上腺炎和原发性肾上腺功能不全：系统评价和最佳治疗方法。
Endocr Pract. 2021 Feb;27(2):165-169. doi: 10.1016/j.eprac.2020.09.016. Epub 2020 Dec 16.
9
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.tislelizumab，一种研究性抗 PD-1 抗体，在实体瘤中的单药 I 期/IB 期研究。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000453.
10
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.替雷利珠单抗联合化疗作为晚期食管鳞癌和胃/胃食管结合部腺癌的一线治疗。
Clin Cancer Res. 2020 Sep 1;26(17):4542-4550. doi: 10.1158/1078-0432.CCR-19-3561. Epub 2020 Jun 19.
引用本文的文献
1
Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China.替雷利珠单抗507例药物不良反应分析：一项基于中国广西数据的真实世界回顾性研究。
PLoS One. 2025 Aug 14;20(8):e0329464. doi: 10.1371/journal.pone.0329464. eCollection 2025.
2
Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature.以严重疼痛和输尿管扩张为主要表现的免疫相关不良反应：替雷利珠单抗诱导的输尿管炎/膀胱炎一例报告及文献复习。
Front Immunol. 2023 Oct 6;14:1226993. doi: 10.3389/fimmu.2023.1226993. eCollection 2023.
3
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review.替雷利珠单抗诱发的严重甲状腺毒症：一例报告及文献综述
Front Oncol. 2023 Oct 2;13:1190491. doi: 10.3389/fonc.2023.1190491. eCollection 2023.
4
Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review.单独使用PD-1抑制剂有效治疗孤立性肾盏尿路上皮癌：一例报告及文献综述
Front Oncol. 2022 May 10;12:866013. doi: 10.3389/fonc.2022.866013. eCollection 2022.
本文引用的文献
1
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.免疫相关不良反应与免疫检查点抑制剂疗效和获益的关系：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Jan;92:102134. doi: 10.1016/j.ctrv.2020.102134. Epub 2020 Dec 3.
2
Tislelizumab: First Approval.替雷利珠单抗：获批上市。
Drugs. 2020 Apr;80(6):617-624. doi: 10.1007/s40265-020-01286-z.
3
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
4
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.抗 PD-1 抗体与 FcγRΙ 的结合对其生物学功能有深远影响。
Cancer Immunol Immunother. 2018 Jul;67(7):1079-1090. doi: 10.1007/s00262-018-2160-x. Epub 2018 Apr 23.
5
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
6
Stomach cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.2001 - 2009年美国不同种族和分期的胃癌生存率：CONCORD - 2研究结果
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):4994-5013. doi: 10.1002/cncr.30881.
7
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.不同免疫检查点抑制剂方案应用后内分泌功能障碍的发生率：系统评价和荟萃分析。
JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064.
8
Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.免疫相关不良反应作为程序性细胞死亡 1 抑制剂治疗非黑色素瘤患者的生物标志物。
Oncologist. 2017 Oct;22(10):1232-1237. doi: 10.1634/theoncologist.2017-0133. Epub 2017 Jun 26.
9
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.全球、区域和国家癌症发病率、死亡率、生命损失年数、失能生存年数以及 32 种癌症组别的伤残调整生命年数，1990 年至 2015 年：全球疾病负担研究的系统分析。
JAMA Oncol. 2017 Apr 1;3(4):524-548. doi: 10.1001/jamaoncol.2016.5688.
10
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
Zotero 插件